Our data show that botulinum toxin A (BoNT/A) didn't influence motor functions in naïve and CCI-exposed rats, but diminished the neuropathic pain-related behavior. The results indicate that BoNT/ A administration diminished the spinal Iba-1 positive cells activation and, in parallel, downregulated IL-1beta. Moreover, we observed that in DRG the protein level of pronociceptive factors (IL-1beta and IL-18) decreased and antinociceptive (IL-10 and IL-1RA) factors increased. Additionally, our behavioral analysis shows that chronic minocycline treatment together with a single BoNT/A injection in CCI-exposed rats has beneficial analgesic effects (M.
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BoNT/A administration diminishes pro-and enhances anti-nociceptive interleukins in the spinal cord and DRG.
The attenuation of non-neuronal cells activation may act as an additional factor in the long-lasting effects of BoNT/A on neuropathy.
Data [1]
Single intraplantar BoNT/A injection significantly attenuated pain-related behavior. Moreover, minocycline enhanced its analgesic properties. The Western blot analysis suggests that CCI-induced the upregulation of IL-18, IL-6 and IL-1beta protein levels in the ipsilateral lumbar spinal cord and DRG, but no changes in IL-18BP, IL-1RA or IL-10 were observed. Interestingly, BoNT/A injection decreased spinal and/or DRG CCI-upregulated levels of IL-18 and IL-1beta and increased the levels of antinociceptive factors (IL-10 and IL-1RA) in the DRG (Scheme 1).
Experimental design, materials and methods

Animals
In our experiments we used male Wistar rats from Charles River (Sulzfeld, Germany).
Neuropathic pain model
Chronic Constriction Injury model [2, 3] .
Drugs
Minocycline hydrochloride (30 mg/kg intraperitoneal, Sigma, USA); scheme administration as described before in Rojewska et al. [4] Botulinum neurotoxin serotype A (300 pg of toxin in 0.9% NaCl per paw; a gift from Prof. C.
Montecucco and from Prof. O. Rossetto, Padova, Italy); administration as described in Mika et al. [3] 2.4. Schemes for the study of repeated minocycline administration combined with a single BoNT/A injection in CCI-exposed rats MC (30 mg/kg) was administered pre-emptively via i.p. injection 16 h and 1 h before CCI and then twice daily for seven days, referred to throughout the manuscript as repeated treatment. We had decided on this administration schedule, since microglial cell inhibitors reduce the activation of these cells more efficiently when the inhibitor is administered before an injury. On day 5 following CCI, the i.pl. injections of 20 μl of saline (0.9% NaCl) or BoNT/A (300 pg of toxin in 0.9% NaCl per paw) were performed. Next, on day 7 following CCI (two days after BoNT/A administration) and 30 min after the last injection of minocycline, behavioral tests (von Frey and cold plate tests) were performed. Tissue collection (spinal cord/DRG) was performed 6 h after the last administration of minocycline (Scheme 2).
